Source: The Pharma Letter

Enterprise Therapeutics: Enterprise Therapeutics' first-in-class TMEM16A potentiator program acquired by Roche

UK-based Enterprise Therapeutics revealed today that its novel TMEM16A potentiator portfolio has been...

Read full article »
Enterprise Therapeutics's Competitors | Enterprise Therapeutics's News | Enterprise Therapeutics's Financials
Stay up-to-date with the latest news on Enterprise Therapeutics
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
John Ford's photo - CEO of Enterprise Therapeutics

CEO

John Ford

CEO Approval Rating

87/100

Read more
Stay up-to-date with the latest news on Enterprise Therapeutics